Recombinant Human Lp-PLA2/PLA2G7 Protein (RP02875)

说明书联系我们收藏

Recombinant Human Lp-PLA2/PLA2G7 Protein was determined by SDS-PAGE with Coomassie Blue, showing a band at 50-65 kDa.

All(1)|

货号: RP02875

详细信息

种属

Human

表达宿主

HEK293 cells

Calculated MW

48.63 kDa

Observed MW

50-60 kDa

标签

C-His

纯度

> 97% by SDS-PAGE.

内毒素

<1EU/μg of the protein by LAL method.

制剂

Lyophilized from a 0.22 μm filtered solution of 50mM NaAc, 150mM NaCl, 10% glycerol (pH 5.0)

描述

Recombinant Human Lp-PLA2/PLA2G7 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Phe22-Asn441) of human Lp-PLA2/PLA2G7 (Accession #NP_001161829.1) fused with a His tag at the C-terminus.

储存

Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week.未开盖的干粉蛋白在 -20°C至-80°C可保存12个月；
复溶之后，蛋白溶液在-20°C及以下可保存3个月，在2-8℃可保存1周。

复溶

Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.收到重组蛋白产品之后请检查蛋白冻干粉末是否贴于瓶底，如果粉末浮起，开盖之前请先低温离心。将蛋白用说明书中指定的缓冲液复溶至0.1-0.5 mg/mL（请注意蛋白复溶浓度不能低于0.1 mg/mL），室温平衡5-10 min保证充分溶解，复溶过程中请不要剧烈涡旋及吹打蛋白溶液。如需长期储存，建议复溶时添加载体蛋白或者稳定剂（如0.1% BSA, 5% HSA, 10% FBS 或者 5% 海藻糖），同时将复溶后的蛋白溶液按照需求进行分装，储存于-20°C至-80°C，随取随用，避免反复冻融。

蛋白复溶计算器

请在蛋白复溶计算器中输入蛋白总质量和所需终浓度，快速计算您需要添加溶液的体积吧！

客户数据及评论 (0)

折叠内容

背景信息

Platelet-activating factor acetylhydrolase, also known as 1-alkyl-2-acetylglycerophosphocholine esterase, 2-acetyl-1-alkylglycero-phosphocholine esterase, Group-VIIA phospholipase A2, LDL-associated phospholipase A2, PAF 2-acylhydrolase, PLA2G7 and PAFAH, is a secreted protein that belongs to the AB hydrolase superfamily and Lipase family. PLA2G7 / PAFAH modulates the action of platelet-activating factor (PAF) by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. It has specificity for substrates with a short residue at the sn-2 position. It is inactive against long-chain phospholipids. PLA2G7 / PAFAH is a potent pro- and anti-inflammatory molecule that has been implicated in multiple inflammatory disease processes, including cardiovascular disease. PLA2G7 also represents an important, potentially functional candidate in the pathophysiology of coronary artery disease (CAD). Defects in PLA2G7 are the cause of platelet-activating factor acetylhydrolase deficiency (PLA2G7 deficiency). It is a trait that is present in 27% of Japanese. It could have a significant physiologic effect in the presence of inflammatory bodily responses.

基因ID

7941

Swiss Prot

Q13093

别名

PLA2G7;LDL-PLA2;LP-PLA2;PAFAD;PAFAH

研究领域